The United Kingdom has issued an urgent recall for blood pressure medication due to a potential risk of hyperkalemia, irregular heartbeats, and even cardiac arrest. The affected medication is Potassium Chloride Extended-Release 750mg Capsules, manufactured by Glenmark Pharmaceuticals, with 114 batches of both the 100 count and 500 count versions being recalled.
The recall is due to the tablets failing to dissolve properly, which means they may not be effective in treating low potassium levels as intended. Hyperkalemia, or dangerously high potassium levels, can lead to irregular heartbeats that could potentially cause cardiac arrest. This is particularly concerning for individuals who rely on potassium chloride regularly to manage conditions such as high blood pressure, heart failure, or kidney failure, as hyperkalemia could lead to more severe, potentially life-threatening adverse events such as cardiac arrhythmia, severe muscle weakness, and death.
Glenmark Pharmaceuticals has not received any reports of hyperkalemia or serious adverse events related to this recall. The capsules are intended for patients with low potassium, also known as hypokalemia, and are packaged in bottles of 100 and 500. Consumers who have these capsules should consult with their physician or healthcare provider before discontinuing use of the product. They should also contact their doctor if they have experienced any problems that may be related to taking or using this drug product.
The recall affects both the 100 count and 500 count Potassium Chloride Extended-Release Capsules, which are manufactured by Glenmark Pharmaceuticals. Consumers are advised to exercise caution and follow the guidance provided by their healthcare providers regarding the use of these medications.
